Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Segment — Net Income (Loss) Attributable to Parent

Similar metrics at other companies

Schering-Plough logo
SGPReporting Segment — Net Income (Loss) Attributable to Parent
-$9.97M-36.7%
Samsara logo
IOTReportable Segment — Net Income (Loss) Attributable to Parent
$44.51M+301%
ALX
ALXReportable Segment — Net Income (Loss) Attributable to Parent
$4.66M-62.1%
Anterix logo
ATEXReportable Segment — Net Income (Loss) Attributable to Parent
$18.52M
Forgent Power Solutions logo
FPSReportable Segment — Net Income (Loss) Attributable to Parent
$24.48M+190%
Andersen Group logo
ANDGReportable Segment — Net Income (Loss) Attributable to Parent
$17.74M-64.9%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Medical expenses7,8997,83215,04715,865
Technical operations expenses165136415234
Stock-based compensation expense14,48410,81825,36422,342
Other segment items(1)25,48057731,6552,477
Interest expense19,51920,46335,38141,253
Interest income(2,289)(2,383)(5,995)(4,608)
Provision for income taxes1,5195,0425,7635,747
Net (loss) income$(15,051)$11,983$(555)$14,400

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent?
Collegium Pharmaceutical, Inc. (COLL) reported segment — net income (loss) attributable to parent of -$15.05M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent changed year-over-year?
Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent decreased by 225.6% year-over-year, from $11.98M to -$15.05M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent?
Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent has grown at a 36.0% compound annual growth rate (CAGR), from -$25M to $62.87M.
What does segment — net income (loss) attributable to parent mean?
This metric represents the final bottom-line profitability of the business segment after accounting for all operating expenses, interest, taxes, and non-operating items. It serves as the primary indicator of the segment's financial health and its ability to generate value for the parent company's shareholders. A consistent positive trend indicates strong operational execution and effective cost management.

Ask your AI about Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude